Immutep Share Price and Company Fundamentals
Last traded: Today at 6:16 AM
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Key Metrics
PE ratio
-
PB ratio
0.90
Dividend yield
-
Beta
2.20
Market cap
$56.00M
Enterprise value
$-11824108.00
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.immutep.com |
| Mailing address | Australia Square Level 32, Suite 32.07 264 George Street Sydney NSW 2000 Australia |
| Phone / Fax | 61 2 8315 7003 / 61 2 8569 1880 |
Dividends
More: Immutep Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Immutep paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.IMM dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Sep 2026, following are the company executives and directors listed on Immutep.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Marc Voigt | CEO, MD, CFO, Chief Business Officer & Executive Director | 52 | |
| Ms. Deanne Miller LLB | COO, General Counsel & Joint Company Secretary | 48 | |
| Dr. Frederic Triebel M.D., Ph.D. | Chief Scientific Officer & Executive Director | 70 | |
| Mr. Christian Mueller BBA, MSc. | Chief Development Officer | ||
| Dr. Stephan Winckels M.D., Ph.D. | Chief Medical Officer | ||
| Ms. Indira Naidu | Joint Company Secretary |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-255.74%
Return on assets
-42.45%
Return on equity
-77.31%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Immutep is 56.00M and its enterprise value is -11824108.00. The enterprise value to revenue ratio of IMM is -0.59. The enterprise value to EBITDA ratio of IMM is 0.15.
The IMM's stocks Beta value is 2.20 making it 120% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Immutep (IMM)
Immutep (ASX:IMM) Frequently Asked Questions
1. What is Immutep's Stock Symbol?
Immutep trades on ASX under the ticker symbol "IMM".
2. What is Immutep's stock price today?
One share of IMM stock can currently be purchased for approximately $0.038.
3. How can I contact Immutep?
Immutep's mailing address is Australia Square Level 32, Suite 32.07 264 George Street Sydney NSW 2000 Australia. The company can be reached via phone at 61 2 8315 7003.
4. What is Immutep's official website?
The official website of Immutep is https://www.immutep.com.